医药板块震荡，恒生创新药ETF（159316）逆势吸筹，半日获2200万份净申购

Group 1 - The Shanghai and Shenzhen 300 Pharmaceutical Health Index decreased by 1.2% at midday, while the CSI Biotech Theme Index fell by 1.5% [1] - The CSI Innovative Drug Industry Index dropped by 1.6%, and the Hang Seng Hong Kong Stock Connect Pharmaceutical Health Comprehensive Index declined by 2.7% [1] - The Hang Seng Innovative Drug ETF (159316) saw a net subscription of 22 million shares during the same period [1] Group 2 - The Hang Seng Innovative Drug Index focuses on leading innovative drug companies in Hong Kong, consisting of no more than 40 stocks involved in innovative drug research and development [2] - The index experienced a decline of 2.8% at midday, with a rolling price-to-earnings ratio of 57.6 times as of July 10, 2023 [2] - The CSI Hong Kong Stock Connect Pharmaceutical Health Comprehensive Index, which includes 50 stocks from the medical device, biopharmaceutical, and chemical drug sectors, fell by 2.7% with a rolling price-to-earnings ratio of 30.2 times [2] Group 3 - The CSI Innovative Drug Industry Index, which focuses on leading innovative drug companies in A-shares, decreased by 1.6% at midday, with a rolling price-to-earnings ratio of 53.1 times [2] - The CSI Biotech Theme Index, which includes up to 50 stocks involved in gene diagnostics, biopharmaceuticals, and other biotechnology sectors, fell by 1.5% with a rolling price-to-earnings ratio of 55.9 times [2] - The Shanghai and Shenzhen 300 Pharmaceutical Health Index, which covers companies in the pharmaceutical and healthcare sectors, decreased by 1.2% at midday, with a rolling price-to-earnings ratio of 32.1 times [3]